KindredBio Announces the Filing of an INAD for Laminitis in Horses

KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses.

SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that plays a critical role in the pathogenesis of equine laminitis.

“Laminitis is a devastating disease,” stated Richard Chin, Chief Executive Officer of Kindred Bio. “It is the cause of career-ending disability or euthanasia for many horses. We believe KIND-005 will be a potent and safe therapy for horses afflicted by this disease. KindredBio is committed to bringing the very best science to companion animals and we are excited to begin our first equine program.”

About KindredBio
“Best Medicines for Our Best Friends”

KindredBio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.

Forward-Looking Statements

Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.

Trademark Acknowledgements

Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.

Denise Bevers
(650) 701-7909